Literature DB >> 15564725

Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.

Diane F Jelinek1, Jaime R Darce.   

Abstract

B lymphocyte stimulator (BLyS), also referred to as B cell activating factor of the TNF family, is a recently identified tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B cell development and homeostasis and it shares significant homology with another TNF superfamily member, a proliferation inducing ligand (APRIL). Currently, three receptors have been identified that transmit signals upon BLyS and APRIL binding and these include B cell maturation antigen, B cell activating factor receptor, and transmembrane activator and CAML interactor. The striking effects of BLyS on normal B cell maintenance and survival and the largely B lineage-restricted pattern of receptor expression, raises the possibility that these TNF family ligands and receptors may be involved not only in B cell autoimmunity, but also in the pathogenesis and maintenance of mature B lineage hematological malignancies. In this article, we will review the spectrum of human B lineage malignancies and discuss current evidence supporting a role for BLyS and APRIL in fueling the growth and survival of specific B cell malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15564725     DOI: 10.1159/000082107

Source DB:  PubMed          Journal:  Curr Dir Autoimmun        ISSN: 1422-2132


  15 in total

1.  B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

Authors:  Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 2.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 3.  The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.

Authors:  M P Cancro
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.

Authors:  Mamta Gupta; Stacey R Dillon; Steven C Ziesmer; Andrew L Feldman; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Blood       Date:  2009-03-25       Impact factor: 22.113

5.  Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.

Authors:  Robert T Woodland; Casey J Fox; Madelyn R Schmidt; Peter S Hammerman; Joseph T Opferman; Stanley J Korsmeyer; David M Hilbert; Craig B Thompson
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

Review 6.  The BLyS family: toward a molecular understanding of B cell homeostasis.

Authors:  John F Treml; Yi Hao; Jason E Stadanlick; Michael P Cancro
Journal:  Cell Biochem Biophys       Date:  2008-11-26       Impact factor: 2.194

7.  APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response.

Authors:  Yanping Xiao; Seiichi Motomura; Eckhard R Podack
Journal:  Eur J Immunol       Date:  2008-12       Impact factor: 5.532

8.  Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.

Authors:  S Yaccoby; A Pennisi; X Li; S R Dillon; F Zhan; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

9.  The up-regulation expression of APRIL is a marker of glottic malignant disease.

Authors:  Meng Lian; Jugao Fang; Demin Han; Hongzhi Ma; Ru Wang; Fan Yang
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-26       Impact factor: 2.503

10.  γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

Authors:  Margot J Pont; Tyler Hill; Gabriel O Cole; Joe J Abbott; Jessica Kelliher; Alexander I Salter; Michael Hudecek; Melissa L Comstock; Anusha Rajan; Bharvin K R Patel; Jenna M Voutsinas; Qian Wu; Lingfeng Liu; Andrew J Cowan; Brent L Wood; Damian J Green; Stanley R Riddell
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.